RU2736823C2 - Двухслойные таблетки, содержащие пробиотики, с двойным высвобождением - Google Patents

Двухслойные таблетки, содержащие пробиотики, с двойным высвобождением Download PDF

Info

Publication number
RU2736823C2
RU2736823C2 RU2017102952A RU2017102952A RU2736823C2 RU 2736823 C2 RU2736823 C2 RU 2736823C2 RU 2017102952 A RU2017102952 A RU 2017102952A RU 2017102952 A RU2017102952 A RU 2017102952A RU 2736823 C2 RU2736823 C2 RU 2736823C2
Authority
RU
Russia
Prior art keywords
layer
dosage form
probiotics
probiotic
release
Prior art date
Application number
RU2017102952A
Other languages
English (en)
Russian (ru)
Other versions
RU2017102952A (ru
RU2017102952A3 (cg-RX-API-DMAC7.html
Inventor
Тимоти ГЭМБЛ
Энтони БЛЭНЧ
Original Assignee
ПРОБИ ЮЭсЭй, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПРОБИ ЮЭсЭй, ИНК. filed Critical ПРОБИ ЮЭсЭй, ИНК.
Publication of RU2017102952A publication Critical patent/RU2017102952A/ru
Publication of RU2017102952A3 publication Critical patent/RU2017102952A3/ru
Application granted granted Critical
Publication of RU2736823C2 publication Critical patent/RU2736823C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2017102952A 2014-07-01 2015-06-29 Двухслойные таблетки, содержащие пробиотики, с двойным высвобождением RU2736823C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462019717P 2014-07-01 2014-07-01
US62/019,717 2014-07-01
PCT/US2015/038254 WO2016003870A1 (en) 2014-07-01 2015-06-29 Bi-layer dual release probiotic tablets

Publications (3)

Publication Number Publication Date
RU2017102952A RU2017102952A (ru) 2018-08-01
RU2017102952A3 RU2017102952A3 (cg-RX-API-DMAC7.html) 2019-02-01
RU2736823C2 true RU2736823C2 (ru) 2020-11-20

Family

ID=55019868

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017102952A RU2736823C2 (ru) 2014-07-01 2015-06-29 Двухслойные таблетки, содержащие пробиотики, с двойным высвобождением

Country Status (17)

Country Link
US (1) US10799541B2 (cg-RX-API-DMAC7.html)
EP (1) EP3164145A4 (cg-RX-API-DMAC7.html)
JP (1) JP2017520577A (cg-RX-API-DMAC7.html)
KR (1) KR20170021350A (cg-RX-API-DMAC7.html)
CN (1) CN106535909A (cg-RX-API-DMAC7.html)
AP (1) AP2016009641A0 (cg-RX-API-DMAC7.html)
AU (1) AU2015284425B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016031000B1 (cg-RX-API-DMAC7.html)
CA (1) CA2951739C (cg-RX-API-DMAC7.html)
CL (1) CL2016003306A1 (cg-RX-API-DMAC7.html)
MA (1) MA40071A (cg-RX-API-DMAC7.html)
MX (1) MX383492B (cg-RX-API-DMAC7.html)
PH (1) PH12016502463A1 (cg-RX-API-DMAC7.html)
RU (1) RU2736823C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201610250WA (cg-RX-API-DMAC7.html)
WO (1) WO2016003870A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201608433B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3048361B1 (fr) * 2016-03-01 2020-12-18 Biose Compositions pour le traitement des candidoses
CN108066296B (zh) * 2016-11-11 2020-11-17 南京益恒寿生命科技有限公司 一种生物学活性组分结肠靶向组合物及其应用
EP3501503A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
BR112020013712A2 (pt) * 2018-01-05 2020-12-01 Nubiyota Llc composições anidras compreendendo uma microbiota co-selecionada, método de uso das mesmas e medicamento
EP3556226B1 (de) * 2018-04-20 2021-01-20 Raab Vitalfood GmbH Komplex-synbiotikum zum aufbau einer gesunden darmflora
CA3102445A1 (en) 2018-06-18 2019-12-26 Probi Ab Lactobacillus plantarum compositions and uses thereof
WO2019243168A1 (en) 2018-06-18 2019-12-26 Probi Ab Probiotic compositions and uses thereof
CN113728088B (zh) 2018-09-13 2025-02-14 未知君有限责任公司 治疗胃肠障碍和炎性障碍的方法和组合物
US20220175893A1 (en) * 2019-03-05 2022-06-09 The Texas A&M University System Combinations of tannase and probiotic formulations and methods of use for improving tannin metabolism
GB201905386D0 (en) 2019-04-16 2019-05-29 Probi Ab Probiotic compositions and uses thereof
GB201908154D0 (en) 2019-06-07 2019-07-24 Probi Ab Lactobacillus compositions and uses thereof
GB201908706D0 (en) 2019-06-18 2019-07-31 Probi Ab Lactobacillus compositions and uses thereof
CN110251474B (zh) * 2019-07-15 2022-01-07 北京工商大学 一种淀粉基大肠靶向双层益生菌片的制备方法
CN117159485A (zh) * 2023-08-11 2023-12-05 江中药业股份有限公司 一种益生菌香口丸及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010008879A2 (en) * 2008-06-24 2010-01-21 Wm. Wrigley Jr. Company Probiotic chewing gum method of manufacture
US8540980B2 (en) * 2001-09-28 2013-09-24 Tntgamble, Inc. Delivery system for biological component

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6037953A (ja) * 1983-08-11 1985-02-27 Herusu Eido:Kk カルシウムを主成分とする栄養補助食品
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
DK0931543T3 (da) 1997-12-19 2002-06-17 Merck Patent Gmbh Flerlagstabletter indeholdende probiotiske mikroorganismer såsom lactobacilli eller bifidobakterier
JP2000302694A (ja) 1999-04-16 2000-10-31 Fuyuki Mitsuyama 医食兼用物質
US6696057B1 (en) 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
US20020044926A1 (en) 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
US20030118547A1 (en) * 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
AU767812B2 (en) 2000-02-04 2003-11-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
EP1151673A3 (en) 2000-05-03 2002-01-02 Societe Des Produits Nestle S.A. Confectionery product having a filling
BR0116349A (pt) 2000-12-18 2003-12-23 Probiohealth Llc Compostos probióticos derivados da cepa ke01 de lactobacillus casei
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
EP1228769A1 (de) 2001-02-02 2002-08-07 Jörg-Peter Prof. Schür Symbiontisches Regenerativum
WO2002080881A2 (en) 2001-04-05 2002-10-17 UNIVERSITé LAVAL Process for making protein delivery matrix and uses thereof
US6627220B2 (en) 2001-07-13 2003-09-30 Scolr, Inc. Tablets containing heat sensitive materials and method for forming thereof
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
CA2778208C (en) * 2001-09-28 2015-11-10 Tntgamble Inc. Delivery system for biological component
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
EP1344458A1 (en) 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Probiotic delivery system
US20030175295A1 (en) 2002-03-15 2003-09-18 Richard Ticktin Composition and method for reducing odors from metabolic processes
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
GB0212975D0 (en) 2002-06-06 2002-07-17 Mars Uk Ltd Mammalian animal composition
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
US20050266069A1 (en) 2002-09-06 2005-12-01 Simmons Donald L Stable probiotic microsphere compositions and their methods of preparation
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
US7105336B2 (en) 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
EP1585502B9 (en) 2002-11-12 2012-05-09 Elan Pharma International Limited Fast-disintegrating solid dosage forms being not friable and comprising pullulan
WO2004087109A1 (ja) 2003-03-27 2004-10-14 Hisamitsu Pharmaceutical Co., Inc. 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
US7025998B2 (en) 2003-05-30 2006-04-11 Rotta Research Laboratorium S.P.A. Phytoestrogens and probiotic for women's health
AU2004267304B2 (en) 2003-08-21 2009-03-12 Otsuka Pharmaceutical Co., Ltd. Lactic acid bacteria having mucosal immunopotentiation effect
GB0330009D0 (en) * 2003-12-24 2004-01-28 Ferrosan As Probiotic tablet formulations
US20080286253A1 (en) 2004-02-09 2008-11-20 Transfert Plus Societe En Commandite Composition Comprising Polymeric Material And Uses Thereof
US20050260181A1 (en) 2004-03-05 2005-11-24 Immunopath Profile, Inc. Compositions and methods for tissue repair
US7854927B2 (en) 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders
GB0410785D0 (en) 2004-05-14 2004-06-16 Glycologic Ltd Improved prebiotic
US20080044481A1 (en) 2004-05-27 2008-02-21 Mordechai Harel Microparticles for Oral Delivery
DE102004026706A1 (de) 2004-05-28 2005-12-15 Merck Patent Gmbh Orale Darreichungsform enthaltend probiotische Bakterien
US20060062774A1 (en) 2004-09-21 2006-03-23 The Procter & Gamble Company Compositions for maintaining and restoring normal urogenital flora
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
EP1885207B1 (en) 2005-05-18 2011-07-06 DSM IP Assets B.V. Compositions for enteral application of microorganisms
EP1928426B1 (de) 2005-09-29 2014-10-01 Merck Patent GmbH Verfahren zur stabilisierung von pharmazeutischen darreichungsformen enthaltend mikroorganismen
US7982066B2 (en) 2005-12-09 2011-07-19 Novalife, Inc. High protein supplement
AU2005339139A1 (en) 2005-12-14 2007-06-21 Oxthera, Inc. Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
US20070184111A1 (en) 2006-02-03 2007-08-09 Pharmavite Llc Hybrid tablet
US8460726B2 (en) 2006-12-18 2013-06-11 Advanced Bionutrition Corporation Dry food product containing live probiotic
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
US20080171085A1 (en) 2007-01-11 2008-07-17 Natrol, Inc. Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration
US8066986B2 (en) * 2007-02-01 2011-11-29 Master Supplements, Inc. Formulations including digestive enzymes and polysorbate surfactants that enhance the colonization of administered probiotics microoganisms
JP2010523555A (ja) 2007-04-04 2010-07-15 シグモイド・ファーマ・リミテッド 「経口医薬組成物」
CA2695366C (en) 2007-08-03 2016-10-04 Shaklee Corporation Nutritional supplement system
WO2009037264A2 (en) 2007-09-17 2009-03-26 Da Volterra Colonic delivery of antimicrobial agents
US9078824B2 (en) 2007-09-24 2015-07-14 The Procter & Gamble Company Composition and method of stabilized sensitive ingredient
US20110223248A1 (en) 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
WO2009092628A1 (en) 2008-01-24 2009-07-30 Nestec S.A. Capsule containing nutritional ingredients and method of delivery of a nutritional liquid from the capsule
CN102014926A (zh) 2008-05-01 2011-04-13 宝洁公司 用于治疗炎性肠病的方法和试剂盒
US8586029B2 (en) 2008-06-04 2013-11-19 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
CA2737247C (en) 2008-09-15 2016-10-11 Labopharm Inc. Starch-based microparticles for the release of agents disposed therein
EP2376065A2 (en) * 2008-11-14 2011-10-19 Portola Pharmaceuticals, Inc. Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof
GB0900551D0 (en) 2009-01-14 2009-02-11 Horton Richard Ingestible compositions and processes of preparation
DK2381799T3 (en) 2009-01-27 2018-10-22 Probiotical Spa PROBIOTIC SUPPLEMENT WITH CHOCOLATE TASTE
KR20170053733A (ko) 2009-02-24 2017-05-16 리터 파마슈티컬즈 인코오포레이티드 프리바이오틱 제제 및 사용 방법
EP2403447B1 (en) 2009-03-06 2019-10-16 Tamarisk Technologies Group, LLC Microencapsulated bioactive agents for oral delivery and methods of use thereof
WO2010105207A1 (en) 2009-03-13 2010-09-16 The Regents Of The University Of California Prebiotic oligosaccharides
US20100330151A1 (en) 2009-06-25 2010-12-30 Mary Elaine Freeland Method of Promoting Gastrointestinal Health Using a Combination of a Probiotic Microorganism and Chocolate
WO2011009848A2 (en) * 2009-07-20 2011-01-27 Bracco Spa Therapeutic use of probiotics
DK2459203T3 (en) 2009-07-30 2019-02-18 Dupont Nutrition Biosci Aps Lactic Acid Bacteria and Bifidobacteria for the Treatment of Endotoxemia
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
MX348611B (es) 2009-12-31 2017-06-21 Milton Trachtman Ira Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
KR101143997B1 (ko) 2010-03-04 2012-05-09 한미사이언스 주식회사 유산균 제제 및 5-ｈｔ4 수용체 효능제를 함유하는 경구 투여용 복합 제제 및 이의 제조방법
US9301982B2 (en) 2010-04-14 2016-04-05 Ganeden Biotech, Inc. Probiotic confection and lipid compositions
EP3202406A1 (en) 2010-04-28 2017-08-09 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
EP2571894A1 (en) 2010-05-19 2013-03-27 North Carolina State University Compositions and methods for the delivery of therapeutic peptides
US20140154312A1 (en) 2010-09-17 2014-06-05 Monica Gulati Oral targetted drug delivery system
WO2012103411A2 (en) * 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
WO2012123770A1 (en) 2011-03-17 2012-09-20 Probiotical S.P.A. Probiotic bacteria having antioxidant activity and use thereof
WO2012154738A1 (en) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Composition and method to improve intestinal health
ES2660775T3 (es) 2011-05-16 2018-03-26 Belano Medical Ag Nuevas bacterias del ácido láctico y composiciones que las contienen contra los resfriados bacterianos
CN202427429U (zh) 2012-01-09 2012-09-12 北京大北农科技集团股份有限公司 一种多层微囊制备设备
US20130295227A1 (en) 2012-05-01 2013-11-07 Robbert H. ter Haar Composition Comprising a Sensitive Ingredient
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US20140112985A1 (en) 2012-10-22 2014-04-24 Polonez Therapeutics Llc Method of prevention and treatment of clostridium difficile infection
CA2940226A1 (en) * 2013-02-22 2014-08-28 The Regents Of The University Of California Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life
WO2014152338A1 (en) * 2013-03-14 2014-09-25 Kabadi Mohan Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8540980B2 (en) * 2001-09-28 2013-09-24 Tntgamble, Inc. Delivery system for biological component
WO2010008879A2 (en) * 2008-06-24 2010-01-21 Wm. Wrigley Jr. Company Probiotic chewing gum method of manufacture

Also Published As

Publication number Publication date
WO2016003870A1 (en) 2016-01-07
AP2016009641A0 (en) 2016-12-31
RU2017102952A (ru) 2018-08-01
EP3164145A4 (en) 2018-01-17
US20170100442A1 (en) 2017-04-13
MX383492B (es) 2025-03-04
US10799541B2 (en) 2020-10-13
RU2017102952A3 (cg-RX-API-DMAC7.html) 2019-02-01
ZA201608433B (en) 2023-05-31
BR112016031000B1 (pt) 2022-01-25
MA40071A (fr) 2016-01-07
EP3164145A1 (en) 2017-05-10
BR112016031000A2 (cg-RX-API-DMAC7.html) 2017-08-22
AU2015284425A1 (en) 2017-01-05
PH12016502463A1 (en) 2017-04-10
CL2016003306A1 (es) 2017-06-09
CN106535909A (zh) 2017-03-22
SG11201610250WA (en) 2017-01-27
AU2015284425B2 (en) 2021-04-01
CA2951739A1 (en) 2016-01-07
CA2951739C (en) 2023-09-19
KR20170021350A (ko) 2017-02-27
JP2017520577A (ja) 2017-07-27
MX2016016773A (es) 2017-06-30

Similar Documents

Publication Publication Date Title
RU2736823C2 (ru) Двухслойные таблетки, содержащие пробиотики, с двойным высвобождением
AU2002330187B2 (en) Delivery system for biological component
US20150050245A1 (en) Methods and delivery system for beneficial additive and subtractive biological agents to promote balanced mammalian gastrointestinal flora
US8540980B2 (en) Delivery system for biological component
US11033589B2 (en) Oral dosage form
AU2002330187A1 (en) Delivery system for biological component
JP2019077705A (ja) プロバイオティクス生物及び／又は治療剤の標的化胃腸管デリバリー
JP5940869B2 (ja) 腸内環境改善有核錠製剤及びハードカプセル製剤
JP2018158947A (ja) 生菌含有製剤
US9750815B2 (en) Composition comprising shellac and/or a salt thereof and sodium starch glycolate
JP2016193893A (ja) 生菌製剤
HK1066969B (en) Delivery system for biological component